NASDAQ:MBVX - MabVax Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.36 -0.41 (-23.16 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$1.77
Today's Range$1.00 - $1.79
52-Week Range$1.00 - $5.70
Volume290,500 shs
Average Volume114,919 shs
Market Capitalization$15.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

Receive MBVX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBVX
CUSIPN/A
Phone858-259-9405

Debt

Debt-to-Equity Ratio1.48
Current Ratio0.21
Quick Ratio0.21

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales81.24
Cash FlowN/A
Price / CashN/A
Book Value$0.15 per share
Price / Book9.07

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-19,020,000.00
Net MarginsN/A
Return on Equity-2,767.01%
Return on Assets-199.42%

Miscellaneous

Employees11
Outstanding Shares8,960,000

MabVax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions

What is MabVax Therapeutics' stock symbol?

MabVax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."

When did MabVax Therapeutics' stock split? How did MabVax Therapeutics' stock split work?

Shares of MabVax Therapeutics reverse split before market open on Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2018. An investor that had 100 shares of MabVax Therapeutics stock prior to the reverse split would have 33 shares after the split.

How were MabVax Therapeutics' earnings last quarter?

MabVax Therapeutics Holdings (NASDAQ:MBVX) issued its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.62) EPS for the quarter. View MabVax Therapeutics' Earnings History.

Who are some of MabVax Therapeutics' key competitors?

Who are MabVax Therapeutics' key executives?

MabVax Therapeutics' management team includes the folowing people:
  • Mr. John David Hansen, Chairman, Pres & CEO (Age 67)
  • Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, CFO & Principal Accounting Officer (Age 71)
  • Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)
  • Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)
  • Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61)

Has MabVax Therapeutics been receiving favorable news coverage?

Media stories about MBVX stock have trended somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MabVax Therapeutics earned a news sentiment score of 0.01 on Accern's scale. They also assigned news headlines about the company an impact score of 44.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are MabVax Therapeutics' major shareholders?

MabVax Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (10.94%). Company insiders that own MabVax Therapeutics stock include Gregory P Hanson, John David Hansen, Paul F Resnick, Paul V Maier, Paul W Maffuid and Philip O Livingston. View Institutional Ownership Trends for MabVax Therapeutics.

Which institutional investors are buying MabVax Therapeutics stock?

MBVX stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for MabVax Therapeutics.

How do I buy shares of MabVax Therapeutics?

Shares of MBVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MabVax Therapeutics' stock price today?

One share of MBVX stock can currently be purchased for approximately $1.36.

How big of a company is MabVax Therapeutics?

MabVax Therapeutics has a market capitalization of $15.86 million and generates $150,000.00 in revenue each year. MabVax Therapeutics employs 11 workers across the globe.

How can I contact MabVax Therapeutics?

MabVax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]


MarketBeat Community Rating for MabVax Therapeutics (MBVX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about MabVax Therapeutics and other stocks. Vote "Outperform" if you believe MBVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBVX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MabVax Therapeutics (NASDAQ:MBVX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/21/2016 forward)

Earnings

MabVax Therapeutics (NASDAQ:MBVX) Earnings History and Estimates Chart

Earnings by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics (NASDAQ MBVX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.62)ViewN/AView Earnings Details
8/14/2017Q2 2017($2.07)($4.41)ViewN/AView Earnings Details
5/24/2017Q1 2017($2.43)($2.55)ViewN/AView Earnings Details
3/1/2017Q4 2016($2.31)ViewN/AView Earnings Details
11/7/2016Q3 2016($2.22)($2.58)ViewN/AView Earnings Details
8/11/2016Q2 2016($4.23)($2.67)ViewN/AView Earnings Details
5/9/2016Q1 2016($3.54)($3.33)$0.20 million$0.15 millionViewN/AView Earnings Details
10/30/2015Q3 2015($4.44)$0.13 millionViewN/AView Earnings Details
8/10/2015Q2 2015($2.67)($6.45)$0.20 million$0.14 millionViewN/AView Earnings Details
5/15/2015Q1 2015($138.78)$0.24 millionViewN/AView Earnings Details
5/15/2014Q1 2014($40.86)ViewN/AView Earnings Details
3/10/2014Q4 2013($30.21)ViewN/AView Earnings Details
11/12/2013Q3 2013($44.40)ViewN/AView Earnings Details
8/9/2013Q2 2013($53.28)ViewN/AView Earnings Details
5/10/2013Q1 2013($81.72)ViewN/AView Earnings Details
3/15/2013Q4 2012($117.24)ViewN/AView Earnings Details
11/9/2012Q312($2.34)ViewN/AView Earnings Details
8/10/2012Q2 2012($197.19)ViewN/AView Earnings Details
5/9/2012Q1 2012($222.78)ViewN/AView Earnings Details
2/23/2012Q4 2011($373.44)($245.40)ViewN/AView Earnings Details
11/3/2011Q3 2011($373.44)($282.75)ViewN/AView Earnings Details
8/11/2011Q2 2011($373.44)($320.07)ViewN/AView Earnings Details
5/16/2011Q1 2011($373.44)($373.44)ViewN/AView Earnings Details
2/22/2011Q4 2010($1,013.61)($400.11)ViewN/AView Earnings Details
11/3/2010Q3 2010($464.13)ViewN/AView Earnings Details
8/6/2010Q2 2010($496.14)ViewN/AView Earnings Details
5/6/2010Q1 2010($533.46)($533.46)ViewN/AView Earnings Details
2/25/2010Q4 2009($640.17)($426.78)ViewN/AView Earnings Details
11/13/2009Q3 2009($586.83)ViewN/AView Earnings Details
8/6/2009Q2 2009($693.51)($565.47)ViewN/AView Earnings Details
5/7/2009Q1 2009($586.83)($773.52)ViewN/AView Earnings Details
2/26/2009Q4 2008($1,120.29)($37.35)ViewN/AView Earnings Details
11/5/2008Q3 2008($1,227.00)($736.20)ViewN/AView Earnings Details
8/11/2008Q2 2008($1,227.00)($1,360.35)ViewN/AView Earnings Details
5/8/2008Q1 2008($1,227.00)($986.91)ViewN/AView Earnings Details
2/27/2008Q4 2007($1,227.00)($1,307.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MabVax Therapeutics (NASDAQ:MBVX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MabVax Therapeutics (NASDAQ MBVX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.76%
Institutional Ownership Percentage: 12.72%
Insider Trading History for MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics (NASDAQ MBVX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/24/2018Paul V MaierDirectorSell35,448$0.85$30,130.8096,351View SEC Filing  
1/16/2018Gregory P HansonInsiderSell41,873$0.92$38,523.16320,013View SEC Filing  
1/16/2018John David HansenCEOSell59,263$0.92$54,521.96536,730View SEC Filing  
1/16/2018Paul F ResnickVPSell3,071$0.92$2,825.3218,333View SEC Filing  
1/16/2018Paul W MaffuidEVPSell38,054$0.92$35,009.68283,703View SEC Filing  
1/12/2018Gregory P HansonCFOSell11,232$0.96$10,782.72478,365View SEC Filing  
1/12/2018John David HansenCEOSell18,582$0.96$17,838.72788,683View SEC Filing  
1/12/2018Paul F ResnickVPSell824$0.96$791.0429,944View SEC Filing  
1/12/2018Paul W MaffuidEVPSell10,207$0.96$9,798.72427,608View SEC Filing  
1/12/2018Philip O LivingstonInsiderSell3,571$0.96$3,428.16293,581View SEC Filing  
1/10/2018Gregory P HansonCFOSell66,550$0.96$63,888.00478,365View SEC Filing  
1/10/2018John David HansenCEOSell110,093$0.96$105,689.28788,683View SEC Filing  
1/10/2018Paul F ResnickVPSell4,879$0.96$4,683.8429,944View SEC Filing  
1/10/2018Paul W MaffuidEVPSell60,478$0.96$58,058.88427,608View SEC Filing  
1/10/2018Philip O LivingstonInsiderSell21,155$0.96$20,308.80293,581View SEC Filing  
4/12/2017John David HansenInsiderSell10,216$2.00$20,432.0061,473View SEC Filing  
4/11/2017John David HansenInsiderSell1,476$2.00$2,952.0072,499View SEC Filing  
4/6/2017John David HansenInsiderSell5,051$2.17$10,960.6777,116View SEC Filing  
3/24/2016Jeffrey V. RavetchDirectorSell131,500$0.60$78,900.00View SEC Filing  
5/29/2015Paul V MaierDirectorBuy5,000$2.30$11,500.00View SEC Filing  
5/22/2015Kenneth M CohenDirectorBuy3,500$2.30$8,050.00View SEC Filing  
12/17/2014Kenneth M CohenDirectorBuy2,500$1.80$4,500.00View SEC Filing  
12/16/2014Gregory P HansonCFOBuy3,000$2.50$7,500.00View SEC Filing  
12/16/2014Robert HoffmanDirectorBuy10,000$2.40$24,000.00View SEC Filing  
9/12/2014Jim J AntonopoulosDirectorSell11,892$6.00$71,352.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MabVax Therapeutics (NASDAQ MBVX) News Headlines

Source:
DateHeadline
MabVax Therapeutics (MBVX) Provides Update on SEC Investigation, Failure to Satisfy Continued Listing RuleMabVax Therapeutics (MBVX) Provides Update on SEC Investigation, Failure to Satisfy Continued Listing Rule
www.streetinsider.com - May 21 at 4:18 PM
MabVax down 27% on accuracy issues in prior financialsMabVax down 27% on accuracy issues in prior financials
seekingalpha.com - May 21 at 4:18 PM
MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and NeuroblastomaMabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma
finance.yahoo.com - May 17 at 9:55 AM
MabVax Therapeutics Presentation from VirtualInvestorConferences.com Now Available for On-Demand ViewingMabVax Therapeutics Presentation from VirtualInvestorConferences.com Now Available for On-Demand Viewing
finance.yahoo.com - May 7 at 9:29 AM
MabVax Therapeutics (MBVX) Announces Private Placement OfferingMabVax Therapeutics (MBVX) Announces Private Placement Offering
www.streetinsider.com - May 3 at 4:15 PM
MabVax Therapeutics Holdings, Inc. Announces Private Placement OfferingMabVax Therapeutics Holdings, Inc. Announces Private Placement Offering
finance.yahoo.com - May 3 at 4:15 PM
MabVax Therapeutics (MBVX) Upgraded by ValuEngine to HoldMabVax Therapeutics (MBVX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 3 at 12:10 AM
MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual MeetingMabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 18 at 9:41 AM
MabVax receives listing deficiency notice from NasdaqMabVax receives listing deficiency notice from Nasdaq
seekingalpha.com - April 14 at 9:51 AM
MabVax Therapeutics (MBVX) Receives Continued Listing Deficiency Notice from NasdaqMabVax Therapeutics (MBVX) Receives Continued Listing Deficiency Notice from Nasdaq
www.streetinsider.com - April 14 at 9:51 AM
MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaqs Minimum Stockholders Equity RequirementsMabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements
finance.yahoo.com - April 13 at 4:18 PM
Form 8-K MABVAX THERAPEUTICS HOLD For: Apr 02Form 8-K MABVAX THERAPEUTICS HOLD For: Apr 02
www.streetinsider.com - April 3 at 10:00 AM
MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 MilestonesMabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones
www.prnewswire.com - April 2 at 8:08 AM
Why MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Ownership Structure Is ImportantWhy MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Ownership Structure Is Important
finance.yahoo.com - March 22 at 4:13 PM
MabVax Therapeutics (MBVX) Announces Acceptance of Three Poster Presentations at AACRMabVax Therapeutics (MBVX) Announces Acceptance of Three Poster Presentations at AACR
www.streetinsider.com - March 16 at 10:01 AM
MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual MeetingMabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 15 at 9:36 AM
With A -68.72% Earnings Drop, Did MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) Really Underperform?With A -68.72% Earnings Drop, Did MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) Really Underperform?
finance.yahoo.com - March 14 at 10:45 AM
MabVax Therapeutics (MBVX) Regains Compliance with NASDAQs $1.00 Minimum Bid PriceMabVax Therapeutics (MBVX) Regains Compliance with NASDAQ's $1.00 Minimum Bid Price
www.streetinsider.com - March 6 at 4:39 PM
MabVax Therapeutics Regains Compliance with NASDAQs $1.00 Minimum Bid Price Maintenance RequirementMabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
finance.yahoo.com - March 6 at 9:33 AM
Short Interest in MabVax Therapeutics Holdings, Inc. (MBVX) Declines By 39.2%Short Interest in MabVax Therapeutics Holdings, Inc. (MBVX) Declines By 39.2%
www.americanbankingnews.com - March 4 at 1:40 AM
MabVax up 22% premarket on early-stage MVT-1075 dataMabVax up 22% premarket on early-stage MVT-1075 data
seekingalpha.com - March 1 at 4:39 PM
MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung CancersMabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers
finance.yahoo.com - February 28 at 9:36 AM
MabVax Therapeutics (MBVX) says 1-for-3 reverse stock split is scheduled to be effective with opening of trading on Friday, February 16MabVax Therapeutics (MBVX) says 1-for-3 reverse stock split is scheduled to be effective with opening of trading on Friday, February 16
www.streetinsider.com - February 15 at 4:25 PM
BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16
www.reuters.com - February 15 at 8:54 AM
MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQs $1.00 Minimum Bid Price Maintenance RequirementMabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
finance.yahoo.com - February 15 at 8:54 AM
MabVax Therapeutics (MBVX) Presents At BIO CEO & Investor Conference - SlideshowMabVax Therapeutics (MBVX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 9:01 AM
MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic CancerMabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer
finance.yahoo.com - February 12 at 8:57 AM
INVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVXINVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX
finance.yahoo.com - February 8 at 4:31 PM
MabVax to Present at BIO CEO & Investor ConferenceMabVax to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:03 AM
MabVax Therapeutics Closes $2.1 Million Private Placement FinancingMabVax Therapeutics Closes $2.1 Million Private Placement Financing
finance.yahoo.com - February 6 at 8:59 AM
MabVax Therapeutics (MBVX) Lifted to Sell at ValuEngineMabVax Therapeutics (MBVX) Lifted to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 10:48 PM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVXIMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX
finance.yahoo.com - January 31 at 4:39 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX)
www.prnewswire.com - January 31 at 1:43 PM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MabVax Therapeutics Holdings, Inc. – MBVXEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MabVax Therapeutics Holdings, Inc. – MBVX
finance.yahoo.com - January 31 at 9:13 AM
All You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) RisksAll You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Risks
finance.yahoo.com - January 31 at 9:13 AM
MabVax Receives Notice of SEC Investigation and Examination of Certain Registration StatementsMabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements
finance.yahoo.com - January 30 at 9:22 AM
MabVax Therapeutics Holdings, Inc. (MBVX) Director Sells $30,130.80 in StockMabVax Therapeutics Holdings, Inc. (MBVX) Director Sells $30,130.80 in Stock
www.americanbankingnews.com - January 24 at 9:24 PM
How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?
finance.yahoo.com - January 23 at 4:14 PM
Gregory P. Hanson Sells 41,873 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) StockGregory P. Hanson Sells 41,873 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 18 at 9:58 PM
Paul W. Maffuid Sells 38,054 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) StockPaul W. Maffuid Sells 38,054 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 18 at 9:58 PM
Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 59,263 Shares of StockInsider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 59,263 Shares of Stock
www.americanbankingnews.com - January 18 at 9:58 PM
MabVax Therapeutics Holdings, Inc. Provides Business Strategy UpdateMabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
finance.yahoo.com - January 16 at 9:19 AM
MabVax Therapeutics Holdings, Inc. (MBVX) Insider Sells $20,308.80 in StockMabVax Therapeutics Holdings, Inc. (MBVX) Insider Sells $20,308.80 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM
MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in StockMabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM
MabVax Therapeutics Holdings, Inc. (MBVX) EVP Sells $58,058.88 in StockMabVax Therapeutics Holdings, Inc. (MBVX) EVP Sells $58,058.88 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM
Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 18,582 Shares of StockInsider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 18,582 Shares of Stock
www.americanbankingnews.com - January 16 at 6:24 AM
John David Hansen Sells 110,093 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) StockJohn David Hansen Sells 110,093 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 16 at 6:24 AM
Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells 66,550 Shares of StockInsider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells 66,550 Shares of Stock
www.americanbankingnews.com - January 16 at 6:24 AM
Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?
finance.yahoo.com - January 4 at 4:56 PM
Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873
finance.yahoo.com - December 22 at 9:22 AM

SEC Filings

MabVax Therapeutics (NASDAQ:MBVX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MabVax Therapeutics (NASDAQ:MBVX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MabVax Therapeutics (NASDAQ MBVX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.